- Covishield-maker Serum Institute of India has joined hands with US-based vaccine developer Novavax
- Two developers are unitedly making Covovax, which is going to be another antidote for SARS-CoV-2 in India, except Covishield and Covaxin
- CEO of the Pune -based vaccine maker has announced the news on his Twitter handle
The world’s biggest vaccine maker Serum Institute of India is currently working on the manufacturing of Covovax – another antidote for SARS-CoV-2. To manufacture the vaccine, the Pune-based vaccine maker has joined hands with Novavax, the famous vaccine developers from the US, revealed Adar Poonawalla, the CEO of the Serum Institute of India.
Notably, the effect of the COVID jab developed by Novavax was 89.3 percent in its UK trial. Meanwhile, the Serum Institute of India has applied for local trials for its under-development vaccine candidate.
Adar Poonawalla, on Saturday, took to his Twitter handle to share the news. His tweet read – “Our partnership for a COVID-19 vaccine with @Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch #COVOVAX by June 2021!”
The Indian government, in a series of tweets on Friday, compared India’s efficiency of handling the pandemic situation with other countries, mentioning “India is the fastest country in the world to vaccinate 3 million people.”
On the other hand, Prime Minister Narendra Modi, during his virtual address at the meeting of the World Economic Forum earlier this week, stated – “India has in these times of crisis fulfilled its global responsibilities from the beginning by setting up infrastructure related to vaccination. So far only two made-in-India vaccines have been introduced, but in the future, many more vaccines will be made available”.